

-----  
**From:** Blaise Corthésy  
**Sent:** Tuesday, September 29, 1998 7:11 AM  
**To:** Morrison, Sherie  
**Subject:** IgA production by a single mammalian cell

Dear Dr. Morrison,

My name is Blaise Corthésy, and I am presently at the Division of Immunology and Allergology of the State Hospital in Lausanne, Switzerland. My group is interested in the heterologous production and structure/function studies of secretory IgA antibodies. From your record of publications, I do not think I am wrong if I write that antibody engineering represents also a major research topic in your lab!

Your paper in PNAS (1997) 94:6364 made it quite clear to me that cells could do the whole job of assembling a whole secretory IgA molecule, and is an attractive alternative to the in vitro reconstitution using purified secretory component and dimeric IgA. As a follow-up to your work, we therefore started examining the possibility to program CHO cells to express and assemble mouse-human chimeric secretory IgA antibodies. The talk given by Dr. Chintalacharuvu this April in San Francisco reinforced the already strong feeling that it is not a "science-fiction" goal. We have now demonstrated that this is feasible, and have written a manuscript reporting on the expression, characterization, and function of CHO-derived monomeric, dimeric, and secretory IgA.

I contact you for the following reasons.

- 1) Would you be interested in having an opportunity to read the manuscript prior to submission? In the case of a positive answer, I would certainly be happy to send the final version to you.
- 2) If you judge the work scientifically sound, would you be kind enough to provide me with advice on how to submit the paper to PNAS. For example, do you know a member I should refer the manuscript to?

As you stated in your PNAS paper, the single mammalian cell system represents a major improvement over the plant system. I think (and please do not take it as an arrogant point of view) that the CHO system we have developed goes one extra step further as compared to your approach. Therefore, I believe that our very similar, yet complementary systems, should be put in prospect through the same journal.

I thank you in advance for considering this e-mail message.

In waiting of your reply, I remain

Sincerely yours.

B. Corthésy

Dr. Blaise Corthésy, Ph.D., P.D., M.E.R.  
Head of the Research Unit  
Division of Immunology and Allergology  
CHUV, BH 18-701  
Rue du Bugnon  
CH-1011 Lausanne  
Switzerland

Phone: ++ 41 21 314 07 83 (Office)  
++ 41 21 314 07 90 (Secretary)  
++ 41 21 314 08 21 / 08 28 (Labs)  
Fax: ++ 41 21 314 08 01  
E-mail: blaise.corthesy@chuv.hospvd.ch

S/N 09/095,385



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Sherie L. Morrison et al.	Examiner:	M. Zeman
Serial No.:	09/095,385	Group Art Unit:	1643
Filed:	June 10, 1998	Docket:	30435.45USU1
Title:	SECRETORY IMMUNOGLOBULIN PRODUCED BY SINGLE CELLS AND METHODS FOR MAKING AND USING SAME		

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a corporation organized and existing under the laws of the State of California, having a place of business at 1111 Franklin Street, 12th Floor, Oakland, CA 94607, certifies that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of:

An assignment from the inventor(s), Sherie L. Morrison and Kote R. Chintalacharuvu to The Regents of the University of California, of the patent application identified above. The assignment was recorded in the U.S. Patent and Trademark Office on June 10, 1998, at Reel 9244, Frame 0755 (copy attached).

The Regents of the University of California owns 100% interest in the above-identified patent application.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, as the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: March 3, 2000

By: Linda S. Stevenson  
Name: Linda S. Stevenson  
Title: Principal Prosecution Analyst

3